Alternatives to Mondae

A low-entry, all-in compounded program with both molecules, one price at every dose and a clean cancel-anytime policy — appealing, though the 'from' price isn't explained and the outcome claims are unverified marketing.

• $8 less per month on average than Mondae
• scores 76/100 against Mondae's 46

Physician-founded and genuinely cheap, with both molecules in a lozenge or a shot and a free MD visit — but a February 2026 FDA misbranding letter is a caveat a mother should read before signing up.

• has an oral option if you would rather not inject
• scores 80/100 against Mondae's 46

The widest menu on our list — injections, sublingual lozenges, daily drops, four brand-name pens and the approved oral GLP-1 — with three compounding pharmacies named, prices published for every plan length, and cancellation terms among the most restrictive we have read.

• offers FDA-approved brand pens, not just compounded
• has an oral option if you would rather not inject
• scores 76/100 against Mondae's 46

One of the lowest listed prices for compounded GLP-1s — $89 a month for semaglutide and $149 for tirzepatide, the same at every dose, with the visit, supplies and shipping included — from a company that received an FDA warning letter in June 2026 and treats every payment as final. Cancellation needs 72 hours' notice, and a documented trinitymeds trademark connection deserves attention.

• offers FDA-approved brand pens, not just compounded
• scores 56/100 against Mondae's 46

Pepti publishes semaglutide prices of $99–$199 a month and tirzepatide prices of $159–$319, depending on dose. Medication, physician care and shipping are included without a separate membership fee.

• has an oral option if you would rather not inject
• scores 58/100 against Mondae's 46

A menopause-focused program that bills insurance for eligible visits. The visit is covered in network or $250 self-pay, and the medication is billed separately from $164 per four-week supply — both figures published. It's built for perimenopause, not the postpartum year.

• offers FDA-approved brand pens, not just compounded
• scores 72/100 against Mondae's 46

Semaglutide: From $79.99/mo; tirzepatide: From $149.99/mo. These are advertised starting amounts; dose, plan duration and renewal conditions need confirmation.

• $7.01 less per month on average than Mondae

Semaglutide: $199/mo; tirzepatide: Starting at $399/mo. Oral semaglutide starts at $299 and oral tirzepatide at $399; confirm your dose, plan length and cancellation terms.

• has an oral option if you would rather not inject
• scores 78/100 against Mondae's 46

Its recorded operator, Trinity HealthCare Supply LLC dba altRx, received FDA warning letter 728236 concerning another website. NextMeds’ current catalog lists semaglutide at $79 a month and tirzepatide at $129, with the same renewal prices. Its $49 headline requires the $588 annual semaglutide plan.

• $8 less per month on average than Mondae